Furthermore, tofacitinib treatment reduced C. jejuni-induced intestinal disease and IFNγ production by human immune cells in humanized mice, collectively suggesting that JAK/STAT pathway inhibition does not compromise protection against C. jejuni. Here, IFNG is linked to intestinal disorder.